Cancer Research UK to trial AstraZeneca asthma drug candidate for kidney cancer

27 December 2013

Cancer Research UK and Cancer Research Technology (the charity’s development and commercialization arm) have reached an agreement with Anglo-Swedish drug major AstraZeneca (LSE: AZN) to take AZD2098, an experimental drug originally designed for asthma, into a clinical trial to treat kidney cancer.

This deal with AstraZeneca will enable the charity’s Drug Development Office to complete preclinical development and carry out early clinical trials of the compound to see if it can benefit kidney cancer patients. Cancer Research UK’s DDO is also funding the early phase trial of AZD2098 in which up to 40 patients will take part commencing in 2015.

Action of AZD2098

AZD2098 targets a molecule found on immune cells called CCR4, which is important for directing these cells to where they need to go. It is thought that in kidney cancer, immune cells move to the tumor because of this molecule. Once the immune cells arrive, the tumor often forces them to become inactive, or worse, help the cancer develop.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK